(Read More: See the Day's Top Percentage Winners & Losers)
Dell - Dell filed a proxy statement which warned of the risks of remaining a public company, as it considers buyout offers from investor Carl Icahn and Blackstone Group as well as the one on the table from CEO Michael Dell and his partners.
Biogen Idec - The drug maker is pricing its new multiple sclerosis drug Tecfidera at $54,900 per year. That's below the $60,000 annual charge for rival drug Gilenya, made by Novartis.
Novartis - Novartis has lost an attempt to win patent protection for its cancer drug Glivec in India. Pharmaceutical companies have been targeting India as an area of potential future growth, and the ruling is seen as possibly having industry-wide implications.
Chesapeake Energy - Chesapeake has named Chief Operating Officer Steven Dixon as interim CEO, replacing Aubrey McLendon, who is expected to step down today. Dixon will be part of a three person search committee to find a permanent replacement.
Apple - Apple has been denied a trademark for its "iPad Mini." The U.S. Patent Office issued a letter saying Apple's case to own that phrase was too weak. Apple has until July 24 to restate its case.
United Continental Holdings - Evercore Partners has lowered the airline's stock to "equal-weight" from "overweight," although it increased its earnings estimates and price target. Evercore said the company is still going through an integration transition, but that it will provide a basis for revenue outperformance for the full year.
Tesla Motor - The automaker said sales of its Model S have exceeded its targets, and now says the first quarter will be profitable on both a GAAP and non-GAAP basis.
EBay - The stock has been upgraded to "buy" from "hold" at Canaccord Genuity, which said eBay has a stable growth engine and that the PayPal unit will provide an upside surprise.
News Corp. - Credit Suisse has upgraded the stock to "outperform" from "neutral."
